Pu-er tea, Liu-bao tea, Fu-zhuan tea, Hua-zhuan tea, Qing-zhuan tea and Hei-zhuan tea as study material, and Tuo tea, Mi-zhuan tea as contrast material, the activity of dark tea on PPARδ and PPARγ model was studied. The results showed that the activation of dark tea to PPARδ & PPARγ receptor is high, and the activating components in dark tea on PPAR can be extracted by hot water. Therefore, dark tea showed a certain role on Hyperlipidemia, anti-obesity, regulation of carbohydrate metabolic and antiatherosclerosis.
SONG Lu-bin
,
HUANG Jian-an
,
LIU Zhong-hua
,
HUANG Hao
,
WANG Kun-bo
. Study on Activity of Dark Tea Extracts on PPARs Model[J]. Journal of Tea Science, 2008
, 28(5)
: 319
-325
.
DOI: 10.13305/j.cnki.jts.2008.05.002
[1] 陈椽. 制茶学[M](第二版). 北京: 中国农业出版社. 1989:6~7.
[2] 陈椽. 中国茶业通史[M]. 北京: 农业出版社. 1984.
[3] 庄晚芳, 陈祖椝, 朱自振. 中国茶叶历史资料选辑[M]. 北京: 农业出版社, 1981.
[4] 纪晓明. 中国黑茶贸易与传播[J]. 茶叶科学, 2006, 26(3): 159~165
[5] 施兆鹏. 茶叶加工学[M]. 北京:中国农业出版社, 1997: 116~156.
[6] Nuclear Receptor Nomenclature Commitee. A unified nomenclature system for the nuclear receptor superfamily[J]. Cell, 1999, 97: 161~163.
[7] Issemann I, Green S.Activation of a number of steroid receptor superfamily by peroxisome proliferators[J]. Nature, 1990, 347: 645~650.
[8] Guan Y, BreyerMD. Targeting peroxisome proliferator- activatedreceptors (PPARs) in kidney and urologic disease[J]. Minerva Urol Nefrol, 2002, 54: 65~79.
[9] 张晓燕, 陈丽红, 管又飞. PPAR家族及其与代谢综合征的关系[J]. 生理科学进展, 2005, 36(1): 6~12.
[10] 傅冬和, 刘仲华, 黄建安, 等. 高通量筛选研究茯砖茶降脂功效[J]. 茶叶科学, 2006, 26(3): 209~2l4.
[11] 傅冬和, 刘仲华, 黄建安, 等. 高通量筛选研究茯砖茶对FXR的作用[J]. 食品科学. 2007, 28(5): 331~334.
[12] 张冬英, 刘仲华, 施兆鹏. 等. 高通量筛选法对普洱茶降血糖血脂作用的研究[J]. 茶叶科学, 2005, 26(1): 49~53.
[13] 傅冬和, 刘仲华, 黄建安, 等. 茯砖茶中几种单体成分功效的高通量筛选研究[J]. 茶叶科学, 2008, 28(1): 39~42.
[14] 徐志红, 蒋志胜. 药物筛选新方法高通量筛选[J]. 生物学通报, 2003, 38(3): 7~9.
[15] 邵成雷, 张玲, 刘慧. 过氧化物酶体增殖激活受体在糖尿病治疗药物研发中的重要作用[J]. 中国药学杂志, 2005, 40(7): 491~494.
[16] 金楠, 王宪. 过氧化物酶体增殖物激活受体与动脉粥样硬化[J]. 生理科学进展, 2004, 35: 13~18.
[17] Spiegelman B M.PPARγ: adipogenic regulator and thiazolidinedione receptor[J]. Diabetes, 1998, 47: 507~514.
[18] Guan Y, Zhang Y, BreyerMD. The role of PPARs in the transcriptional control of cellular processes[J]. DrugNews and Perspective, 2002, 15: 147~154.
[19] Moller DE.New drug targets for type 2 diabetes and the metabolic syndrome[J]. Nature, 2001, 414: 821~827.
[20] 陈娜, 吴英良. PPARδ的结构及其生物学功能与疾病[J]. 中国药理学通报, 2006, 22(9): 1035~1038.
浙公网安备 33019902000101号 
